Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: Results from a randomized controlled trial

Journal of Hepatology

Volumn 59, Issue 1, 2013, Pages 153-159

  Chrispijn, Melissa ^a   Gevers, Tom J G ^a   Hol, Jeroen C ^a   Monshouwer, Rene ^a   Dekker, Heleen M ^a   Drenth, Joost P H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ADPKD; Everolimus mTOR inhibitors; Octreotide; PCLD; Polycystic liver disease; Randomized controlled trial; RCT; Somatostatin analogues

Indexed keywords

EVEROLIMUS; OCTREOTIDE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; ASCITES; BLOATING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; FEVER; GLUCOSE BLOOD LEVEL; HUMAN; INFECTION; KIDNEY FUNCTION; LEUKOPENIA; LIVER POLYCYSTIC DISEASE; LIVER WEIGHT; LOOSE FECES; MALAISE; MALE; MONOTHERAPY; MOUTH PAIN; MYALGIA; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PRIORITY JOURNAL; PRURITUS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STOMATITIS; SWELLING; THROMBOCYTOPENIA; TREATMENT DURATION; VERTIGO; VOLUMETRY;

ADULT; CYSTS; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KIDNEY; LIVER; LIVER DISEASES; MALE; MIDDLE AGED; OCTREOTIDE; ORGAN SIZE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; SIROLIMUS; TREATMENT OUTCOME;

EID: 84879135282     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.03.004     Document Type: Article

References (22)

1. L. van Keimpema, D.B. de Koning, B. van Hoek, A.P. van den Berg, M.G. van Oijen, and R.A. de Man Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases Liver Int 31 2011 92 98
2. J.P. Drenth, J.A. Martina, K.R. Van de, J.S. Bonifacino, and J.B. Jansen Polycystic liver disease is a disorder of cotranslational protein processing Trends Mol Med 11 2005 37 42
3. V.E. Torres, P.C. Harris, and Y. Pirson Autosomal dominant polycystic kidney disease Lancet 369 2007 1287 1301
4. J.P. Drenth, M. Chrispijn, D.M. Nagorney, P.S. Kamath, and V.E. Torres Medical and surgical treatment options for polycystic liver disease Hepatology 52 2010 2223 2230
5. A.Y. Gong, P.S. Tietz, M.A. Muff, P.L. Splinter, R.C. Huebert, and M.Z. Strowski Somatostatin stimulates ductal bile absorption and inhibits ductal bile secretion in mice via SSTR2 on cholangiocytes Am J Physiol Cell Physiol 284 2003 C1205 C1214
6. J.M. Banales, T.V. Masyuk, P.S. Bogert, B.Q. Huang, S.A. Gradilone, and S.O. Lee Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease Am J Pathol 173 2008 1637 1646
7. J.M. Banales, T.V. Masyuk, S.A. Gradilone, A.I. Masyuk, J.F. Medina, and N.F. Larusso The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD) Hepatology 49 2009 160 174
8. D. Alvaro, A. Gigliozzi, and A.F. Attili Regulation and deregulation of cholangiocyte proliferation J Hepatol 33 2000 333 340
9. T.V. Masyuk, A.I. Masyuk, V.E. Torres, P.C. Harris, and N.F. Larusso Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3′,5′-cyclic monophosphate Gastroenterology 132 2007 1104 1116
10. L. van Keimpema, F. Nevens, R. Vanslembrouck, M.G. van Oijen, A.L. Hoffmann, and H.M. Dekker Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial Gastroenterology 137 2009 1661 1668
11. M.C. Hogan, T.V. Masyuk, L.J. Page, V.J. Kubly, E.J. Bergstralh, and X. Li Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease J Am Soc Nephrol 21 2010 1052 1061
12. A. Caroli, L. Antiga, M. Cafaro, G. Fasolini, A. Remuzzi, and G. Remuzzi Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide Clin J Am Soc Nephrol 5 2010 783 789
13. T.J. Gevers, and J.P. Drenth Somatostatin analogues for treatment of polycystic liver disease Curr Opin Gastroenterol 27 2011 294 300
14. M.C. Hogan, T.V. Masyuk, L. Page, D.R. Holmes III, X. Li, and E.J. Bergstralh Somatostatin analog therapy for severe polycystic liver disease: results after 2 years Nephrol Dial Transplant 27 2012 3532 3539
15. J.M. Shillingford, N.S. Murcia, C.H. Larson, S.H. Low, R. Hedgepeth, and N. Brown The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease Proc Natl Acad Sci U S A 103 2006 5466 5471
16. Q. Qian, H. Du, B.F. King, S. Kumar, P.G. Dean, and F.G. Cosio Sirolimus reduces polycystic liver volume in ADPKD patients J Am Soc Nephrol 19 2008 631 638
17. A.L. Serra, D. Poster, A.D. Kistler, F. Krauer, S. Raina, and J. Young Sirolimus and kidney growth in autosomal dominant polycystic kidney disease N Engl J Med 363 2010 820 829
18. G. Walz, K. Budde, M. Mannaa, J. Nurnberger, C. Wanner, and C. Sommerer Everolimus in patients with autosomal dominant polycystic kidney disease N Engl J Med 363 2010 830 840
19. M. Chrispijn, and J.P. Drenth Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial Trials 12 2011 246
20. T. Eisen, C.N. Sternberg, C. Robert, P. Mulders, L. Pyle, and S. Zbinden Targeted therapies for renal cell carcinoma: review of adverse event management strategies J Natl Cancer Inst 104 2012 93 113
21. M. Chrispijn, F. Nevens, T.J. Gevers, R. Vanslembrouck, M.G. van Oijen, and W. Coudyzer The long-term outcome of patients with polycystic liver disease treated with lanreotide Aliment Pharmacol Ther 35 2012 266 274
22. L. Friedrich, F. Barbey, M. Pascual, and J.P. Venetz Absence of mTOR inhibitor effect on hepatic cyst growth: a case report of a kidney transplant recipient with autosomal dominant polycystic kidney disease Case Rep Transplant 2012 2012 513025